Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF TECHNICAL OPS OFFICER | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,299 |
Ending reported balance
After 2026-07-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 2,464 · Balance 62,763 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Row 2 · 2026-07-09 · Sale · Disposed 2,464 · Balance 60,299 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.54 · Expires 2035-01-02 | Direct | 45,036 |
Reported balance
After 2026-07-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-09 · Exercise / conversion · Disposed 2,464 · Balance 45,036 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,899 |
Reported balance
Holding disclosure · report date 2026-07-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,899 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,464 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001578850-26-000023 · form4-07132026_050701.xml · derivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,036 Underlying: Common Stock · 2,464 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,464 | $90.25 | $222,376.00 |
DisclosureSEC source: 0001578850-26-000023 · form4-07132026_050701.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,299 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,464 | $46.54 | $114,674.56 |
DisclosureSEC source: 0001578850-26-000023 · form4-07132026_050701.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,613 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · derivative · entry 17 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,063 Underlying: Common Stock · 24,613 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F12 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,288 | $89.44 | $830,718.72 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 12 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,299 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $89.29 to $89.75 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,369 | $89.03 | $1,012,182.07 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 11 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,587 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $88.29 to $89.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,956 | $87.17 | $344,844.52 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 10 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,956 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $87.00 to $87.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 24,613 | $39.42 | $970,244.46 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 9 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,474 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · derivative · entry 16 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,676 Underlying: Common Stock · 2,474 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F12 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,876 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · derivative · entry 15 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,876 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F11 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 811 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · derivative · entry 14 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 Underlying: Common Stock · 811 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F11 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,474 | $87.03 | $215,312.22 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 8 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,299 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $87.00 to $87.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,474 | $39.42 | $97,525.08 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 7 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,090 | $86.32 | $870,968.80 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 6 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,299 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.03 to $86.74 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,786 | $85.35 | $749,885.10 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 5 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,389 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 18,876 | $38.10 | $719,175.60 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 385 | $86.34 | $33,240.90 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,299 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.02 to $86.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 426 | $85.28 | $36,329.28 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,684 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 811 | $38.10 | $30,899.10 |
DisclosureSEC source: 0001578850-26-000021 · form4-07082026_050702.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2 · balance_after: Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578850-26-000019 · form4-06302026_050601.xml · derivative · entry 7 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,687 Underlying: Common Stock · 7,718 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 412 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578850-26-000019 · form4-06302026_050601.xml · derivative · entry 6 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,405 Underlying: Common Stock · 412 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,718 | $85.26 | $658,036.68 |
DisclosureSEC source: 0001578850-26-000019 · form4-06302026_050601.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.75 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,718 | $38.10 | $294,055.80 |
DisclosureSEC source: 0001578850-26-000019 · form4-06302026_050601.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 412 | $85.23 | $35,114.76 |
DisclosureSEC source: 0001578850-26-000019 · form4-06302026_050601.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.07 to $85.30 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 412 | $38.10 | $15,697.20 |
DisclosureSEC source: 0001578850-26-000019 · form4-06302026_050601.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · derivative · entry 17 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,150 Underlying: Common Stock · 100 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F9 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,859 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · derivative · entry 16 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,817 Underlying: Common Stock · 19,859 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,001 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · derivative · entry 15 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,676 Underlying: Common Stock · 1,001 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $87.00 | $8,700.00 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 12 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 100 | $39.42 | $3,942.00 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 11 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,337 | $86.51 | $980,763.87 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 10 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.02 to $86.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,522 | $85.26 | $726,585.72 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 9 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,474 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 19,859 | $38.10 | $756,627.90 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 8 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 419 | $86.39 | $36,197.41 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 7 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.23 to $86.59 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 582 | $85.24 | $49,609.68 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 6 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,556 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.84 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,001 | $38.10 | $38,138.10 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 5 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,922 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · derivative · entry 14 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,677 Underlying: Common Stock · 4,922 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 401 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · derivative · entry 13 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,599 Underlying: Common Stock · 401 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,922 | $85.03 | $418,517.66 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,922 | $38.10 | $187,528.20 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 401 | $85.01 | $34,089.01 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 401 | $38.10 | $15,278.10 |
DisclosureSEC source: 0001578850-26-000017 · form4-06262026_050601.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,749 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001578850-26-000014 · form4-06242026_050601.xml · derivative · entry 5 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,751 Underlying: Common Stock · 23,749 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F4 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,619 | $81.21 | $943,578.99 |
DisclosureSEC source: 0001578850-26-000014 · form4-06242026_050601.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $81.00 to $81.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 12,130 | $80.61 | $977,799.30 |
DisclosureSEC source: 0001578850-26-000014 · form4-06242026_050601.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,756 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 23,749 | $25.69 | $610,111.81 |
DisclosureSEC source: 0001578850-26-000014 · form4-06242026_050601.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 80 | $70.30 | $5,624.00 |
DisclosureSEC source: 0001578850-26-000012 · form4-04032026_050402.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,137 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 12,530 | $69.50 | $870,835.00 |
DisclosureSEC source: 0001578850-26-000012 · form4-04032026_050402.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,217 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.26 to $70.13 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 39,393 | $68.89 | $2,713,783.77 |
DisclosureSEC source: 0001578850-26-000012 · form4-04032026_050402.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,747 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.26 to $69.26 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,989 | $63.38 | $252,822.82 |
DisclosureSEC source: 0001578850-26-000010 · form4-03092026_050301.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,737 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 26, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.